Table 2 Independent genetic variants with suggestive interaction of current combined EPT use on breast cancer after LD-based clumping.

From: Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

SNP rsida

Chr

Positiona

A1

A2

EAF

Nearby genes

OR

95% CI

P-value

rs4865075

4

57113130

A

G

0.76

KIAA1211

1.25

(1.14, 1.36)

5.50E−07

rs7519793

1

147301176

C

T

0.40

RP11-433J22.3, RP11-314N2.2

1.21

(1.12, 1.31)

1.59E−06

rs4871847

8

22964316

A

G

0.30

TNFRSF10C

0.82

(0.85, 0.89)

1.77E−06

rs2165698

13

88558039

T

C

0.54

TET1P1, RP11-545P6.2

1.22

(1.12, 1.33)

2.76E−06

rs34954573

3

76118773

CT

C

0.56

ROBO2

0.82

(0.76, 0.89)

3.17E−06

rs10836138

11

33996495

C

T

0.47

LMO2, CAPRIN1

0.83

(0.77, 0.90)

3.37E−06

rs4844958

1

210361388

A

G

0.47

SYT14, SERTAD4-AS1

1.20

(1.11, 1.30)

3.45E−06

rs145119792

4

138681096

G

T

0.99

RP13-884E18.4, RP11-793B23.1

2.61

(1.74, 3.91)

3.71E−06

rs2372593

2

216596263

G

A

0.93

LINC00607

1.42

(1.22, 1.66)

4.52E−06

rs1359939

1

177820861

G

A

0.68

RP11-63B19.1, SEC16B

1.22

(1.12, 1.33)

4.71E−06

rs1398476

8

5608189

C

A

0.79

RP11-281H11.1, RP11-728L1.1

0.79

(0.81, 0.87)

4.81E−06

rs148904951

12

78267629

T

G

0.03

NAV3

2.05

(1.51, 2.78)

4.90E−06

rs41380949

3

105175646

A

G

0.10

ALCAM

1.36

(1.19, 1.55)

5.11E−06

rs116807456

1

232593292

A

G

0.02

SIPA1L2

0.49

(0.36, 0.66)

5.76E−06

rs79505632

8

11079796

C

G

0.05

AF131215.8, LINC00529

0.66

(0.55, 0.79)

6.17E−06

rs146727380

3

21750977

GAAAAC

GAAAACAAAAC

0.51

ZNF385D

0.82

(0.76, 0.90)

6.61E−06

rs146444598

6

29912227

TGGA

T

0.52

HLA-A

1.19

(1.10, 1.29)

6.85E−06

rs9690705

7

151595436

G

A

0.42

PRKAG2-AS1, RNU6-604P

1.20

(1.11, 1.29)

7.46E−06

rs77773073

3

44919409

G

A

0.86

TGM4, LRRN1

1.28

(1.15, 1.43)

7.65E−06

rs1772028

14

101693861

C

G

0.49

RP11-8L8.1, CTD-2561F5.1

0.84

(0.78, 0.91)

9.16E−06

rs7522223

1

25217994

T

C

0.15

CLIC4, RUNX3

0.78

(0.70, 0.87)

9.26E−06

  1. SNP single nucleotide polymorphism, Chr chromosome, A1 reference allele, A2 alternative allele, EAF estimated allele frequency for alternative allele, OR odds ratios per alternative allele with current combined estrogen–progesterone hormone therapy use on breast cancer risk, 95% CI corresponding 95% confidence intervals;
  2. arsid and position are based on the Genome Reference Consortium Human genome build 37.
Back to article page